Mesa Laboratories (MLAB) Projected to Post Earnings on Monday

Mesa Laboratories (NASDAQ:MLAB) will likely be announcing its Q1 2027 results after the market closes on Monday, August 10th. Analysts expect the company to post earnings of $2.63 per share and revenue of $60.8670 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.78 by ($0.25). The firm had revenue of $63.72 million during the quarter, compared to analysts’ expectations of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same quarter in the prior year, the company posted ($1.31) earnings per share.

Mesa Laboratories Stock Performance

MLAB stock opened at $102.65 on Friday. The company has a market capitalization of $574.84 million, a P/E ratio of 85.54 and a beta of 0.92. Mesa Laboratories has a 1-year low of $58.83 and a 1-year high of $113.99. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. The business has a 50-day moving average price of $100.33 and a 200 day moving average price of $95.15.

Mesa Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories’s payout ratio is currently 53.33%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $94.00.

Insider Activity at Mesa Laboratories

In other Mesa Laboratories news, CFO John Sakys sold 2,827 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the completion of the transaction, the chief financial officer owned 19,785 shares of the company’s stock, valued at $1,770,757.50. This trade represents a 12.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Lyndsey Elizabeth Crennen sold 442 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $39,559.00. Following the completion of the sale, the chief accounting officer directly owned 2,020 shares in the company, valued at approximately $180,790. The trade was a 17.95% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 8,277 shares of company stock valued at $770,122. Corporate insiders own 2.80% of the company’s stock.

Hedge Funds Weigh In On Mesa Laboratories

A number of institutional investors and hedge funds have recently made changes to their positions in MLAB. Invesco Ltd. grew its holdings in Mesa Laboratories by 11.7% during the 4th quarter. Invesco Ltd. now owns 12,845 shares of the medical instruments supplier’s stock worth $1,008,000 after acquiring an additional 1,350 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Mesa Laboratories in the 4th quarter valued at $989,000. Tudor Investment Corp ET AL lifted its position in shares of Mesa Laboratories by 332.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 27,426 shares of the medical instruments supplier’s stock worth $2,153,000 after purchasing an additional 21,085 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Mesa Laboratories during the 4th quarter worth $1,062,000. Finally, Numerai GP LLC grew its stake in shares of Mesa Laboratories by 313.0% during the fourth quarter. Numerai GP LLC now owns 14,909 shares of the medical instruments supplier’s stock worth $1,170,000 after purchasing an additional 11,299 shares in the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.